Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

The medicinal use of enigninactone a and b as an α-glucosidase inhibitor and then for the preparation of hypoglycemic drugs

A kind of technology of engeninolactone and hypoglycemia, which is applied in the field of medicine to achieve the effect of high inhibition intensity

Active Publication Date: 2022-02-15
南京泓纬医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no report that enigninactone A and B are used as α-glucosidase inhibitors and then used to prepare hypoglycemic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The medicinal use of enigninactone a and b as an α-glucosidase inhibitor and then for the preparation of hypoglycemic drugs
  • The medicinal use of enigninactone a and b as an α-glucosidase inhibitor and then for the preparation of hypoglycemic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] 1. Test materials

[0019] α-glucosidase (yeast) was purchased from Shanghai Jingke Chemical Technology Co., Ltd.

[0020] p-nitrobenzene-β-D-galactopyranoside and DMSO were analytically pure.

[0021] The purity of acarbose, enininactone A and enininactone B is not less than 98%.

[0022] The brand of 96-well plate is Corning.

[0023] 2. Test method

[0024] According to the method disclosed in the literature (Study on lanolin-type triterpenoids in Chizhi and its α-glucosidase inhibitory activity, Chinese herbal medicine, 2017):

[0025] Solution preparation: take α-glucosidase to prepare 0.2U / mL enzyme solution; take p-nitrophenyl-β-D-galactopyranoside (PNPG) to prepare 2.5mM PNPG solution; prepare pH6 according to conventional formula .8 potassium phosphate buffer solution.

[0026] The inhibition test was carried out in a 96-well plate, and the 140 μL potassium phosphate buffer solution (pH6.8) reaction system in each well contained 20 μL of 0.2 U / mL α-glucosi...

Embodiment 2

[0033] A hypoglycemic tablet, the formula of which comprises 10 mg of cyanolactone A or 10 mg of cyanolactone B, 90 g of starch, and 3 g of magnesium stearate.

[0034] Preparation process: Take enigninactone A or enigninactone B, add starch and magnesium stearate, mix evenly, granulate, dry, and compress into tablets.

Embodiment 3

[0036] A hypoglycemic capsule, the formula of which comprises 10 mg of enigninactone A or enigninactone B, 90 g of starch and 3 g of magnesium stearate.

[0037] Preparation process: Take enigninactone A or enigninactone B, add starch and magnesium stearate, mix evenly, granulate, dry, and pack into capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the medical use of enigninactone A and B as an α-glucosidase inhibitor and further used in the preparation of hypoglycemic drugs. The research result of the embodiment of the present invention shows that enigninactone A and enigninactone B all have significant inhibitory effect on α-glucosidase, and the inhibitory intensity of the two is better than that of the positive drug acarbose, and both can For the preparation of hypoglycemic drugs. Further, compared with enigninactone A, enigninactone B has a significantly higher inhibitory intensity on α-glucosidase, which is more than 15 times that of enigninactone A, and is a more promising hypoglycemic drugs.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the medical use of cylindrolactone A and B as an α-glucosidase inhibitor and further used to prepare hypoglycemic drugs. Background technique [0002] Enininactone A and eninininactone B are a pair of isomers, the difference is only in one connection -OH and -CH 3 The chirality of the carbon atom is different, and the chemical structural formulas of cinnamate A and B are as follows: [0003] [0004] Starch in food is digested by salivary enzymes in the mouth, acid in the stomach, and tryptic amylase in the digestive tract into oligosaccharides, disaccharides, and trisaccharides containing a few glucose molecules, and finally passes through the brush border membrane of the small intestinal villi epithelial cells Existing membrane-bound enzymes, maltotriose and disaccharide hydrolase (α-glucosidase, sucrase, maltase), etc. are decomposed into monosaccharides, and glucose, l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/365A61P3/10
CPCA61K31/365A61P3/10
Inventor 朱阳晨赵玲
Owner 南京泓纬医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com